Jasper Therapeutics (NASDAQ:JSPR) Now Covered by BTIG Research

BTIG Research started coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $90.00 price objective on the stock.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. HC Wainwright reaffirmed a buy rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Wednesday, May 15th. Stifel Nicolaus began coverage on shares of Jasper Therapeutics in a report on Thursday, June 27th. They issued a buy rating and a $86.00 target price for the company. Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a report on Thursday, March 28th. They set an outperform rating and a $70.00 price target on the stock. Finally, TD Cowen started coverage on Jasper Therapeutics in a research report on Monday, March 18th. They set an outperform rating for the company. Eleven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of Buy and a consensus target price of $69.56.

Jasper Therapeutics Trading Up 0.9 %

JSPR opened at $20.05 on Monday. The company has a market cap of $301.95 million, a price-to-earnings ratio of -3.56 and a beta of 2.21. The company’s fifty day moving average price is $22.96 and its two-hundred day moving average price is $20.36. Jasper Therapeutics has a 1-year low of $4.00 and a 1-year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Tuesday, May 14th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.23. As a group, equities analysts forecast that Jasper Therapeutics will post -4.41 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Ieq Capital LLC bought a new stake in shares of Jasper Therapeutics in the fourth quarter worth $43,000. Monaco Asset Management SAM bought a new stake in shares of Jasper Therapeutics during the 4th quarter valued at about $197,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics during the 1st quarter valued at about $306,000. Fernwood Investment Management LLC lifted its stake in shares of Jasper Therapeutics by 8.8% in the 4th quarter. Fernwood Investment Management LLC now owns 494,706 shares of the company’s stock worth $390,000 after purchasing an additional 40,000 shares during the period. Finally, Concurrent Investment Advisors LLC purchased a new position in shares of Jasper Therapeutics in the first quarter worth approximately $599,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.